Svati H. Shah, MD, MHS

Associate Director of Clinical Translation
Duke Molecular Physiology Institute


Professor of Medicine
Associate Dean of Genomics and Director of Precision Genomics Collaboratory
Director, Duke Adult Cardiovascular Genetics Clinic
Co-Director, Translational Research, Duke Molecular Physiology Institute
Vice-Chief, Translational Research, Division of Cardiology
Duke University School of Medicine


Carmichael Building

919 684 2859


Dr. Shah is Professor of Medicine and Associate Dean for Genomics at Duke University, where she is also Director of the Precision Genomics Collaboratory, Director of the Adult Cardiovascular Genetics Clinic, and the Vice-Chief of Translational Research in the Division of Cardiology. Her research laboratory focuses on the molecular epidemiology of cardiometabolic diseases, using integrated 'omics technologies including genomics and metabolomics, to identify novel biomarkers and mechanisms of disease pathogenesis. Dr. Shah also works closely as a volunteer for the American Heart Association including serving as Chair of the AHA’s Research Committee, former Chair of the Genomic and Precision Medicine Council, and she is an Associate Editor for Circulation.

MHS, Medical Genomics, Duke University, Durham, NC
MD, University of Washington, Seattle, WA
MHS., Johns Hopkins University, Baltimore, MD

My research laboratory studies the molecular epidemiology of cardiovascular disease, utilizing metabolomic, genomic and bioinformatics methods in a "systems biology" approach to identify novel biomarkers and mechanisms of cardiometabolic disease pathogenesis. The laboratory encompasses a statistical analytic component, a clinical research component, as well as a wet lab component for genomic analyses. We work on several cardiometabolic phenotypes, including coronary artery disease, acute coronary syndrome, cardiovascular events, aortic stenosis, aortic aneurysm, pulmonary hypertension, type II diabetes, and heart failure. We are involved in molecular profiling in cardiometabolic cohorts including CATHGEN (N=9500 individuals referred to cardiac catheterization), EPGEN (N=2500 individuals undergoing electrophysiologic procedures); and in clinical trial biorepositories through collaborations with the Duke Clinical Research Institute (DCRI) including Trilogy (clinical trial of acute coronary syndrome), Navigator (clinical trial to prevent transition from prediabetes to diabetes), and PROMISE (clinical trial of imaging in suspected CAD). More recently, we have expanded our molecular epidemiology efforts to identify disease biomarkers in global populations and are currently conducting a small prospective study of metabolic and genomic biomarkers of type II DM and CAD in Gurgaon, India in collaboration with Medanta Hospital through collaborations with the Duke Global Health Institute (DGHI). Through work with the Duke Heart Center, we also care of patients with hereditary cardiovascular disorders in the Duke Adult Cardiovascular Genetics Clinic. Our work has resulted in the identification of novel CAD genes; metabolic biomarkers that predict incident CVD events; and novel pathways of CVD event pathogenesis.


Erin Rhodes


Kaitlyn Amos

Caroline de Calvacamp

Stephanie Giamberardino

Melissa Hurdle

Lydia Kwee, PhD

Maggie Nguyen

Postdocs / Fellows

Jawan Abdulrahim, MD

Nathan Bihlmeyer, PhD

Navid Nafissi, MD

Megan Ramaker, PhD

Jessica Regan, MD

Lauren Truby, MD

Other Research Team Members

Kamrouz Ghadimi, MD

Albert Sun, MD

Simon G. Gregory, PhD (Duke)
Elizabeth Hauser, PhD (Duke)
William E. Kraus, MD (Duke)
Christopher B. Newgard, PhD (Duke)
James Bain, PhD (Duke)
Michael Muehlbauer (Duke)
Redford Williams, PhD (Duke)
Geoffrey Ginsburg, MD, PhD (Duke)
Laura Svetkey, MD (Duke)
Patrick Pun, MD (Duke)
L. Kristin Newby, MD (Duke)
Mark Chan, MD (Singapore)
Robert Gerszten, MD (Massachusetts General Hospital)
Sanjay Mittal, MD (Medanta Hospital, India)
Ravi Kasliwal, MD (Medanta Hospital, India)
Jennifer Wu, MD, MPH (UNC)